Supreme Court flags ₹27,000 MRP on cancer drug with ₹2,700 retailer price
The Supreme Court has scrutinised medicine pricing after citing a cancer drug with a ₹27,000 MRP against a ₹2,700 price to retailer. The court questioned margin distribution across manufacturers, stockists, retailers and hospitals; the Indian Pharmaceutical Alliance said drugmakers do not retain the full spread.
What happened
Indian Pharmaceutical Alliance · The Supreme Court scrutinised steep medicine markups, citing a cancer drug with a ₹27,000 MRP versus ₹2,700 PTR. It questioned
Key facts
- ₹27,000 MRP
- ₹2,700 price to retailer (PTR)
Why this matters
Corporate development teams should prioritise partnerships or targets with transparent pricing, compliant distribution controls and lower dependence on opaque specialty-drug margin pools.
What to watch
- A Supreme Court order directing a government response, committee, audit, affidavit or time-bound review of pharmaceutical margins.
- NPPA, Department of Pharmaceuticals, CDSCO or state drug-controller consultations on trade margins, MRP disclosure or oncology-drug pricing.
- Expansion of price-control coverage under the National List of Essential Medicines or use of extraordinary price-control powers.
- Requests for manufacturer, stockist, retailer or hospital invoices in specific cancer-drug cases.
- Public disclosure of additional large MRP-versus-trade-price examples and consumer litigation around overcharging.
- Announcements by major pharmacy chains, hospital groups or drugmakers of margin disclosures or price-reduction programs.
- Map exposure to medicines with unusually large MRP-to-price-to-retailer gaps, especially oncology, injectables, chronic-care brands and hospital-dispensed products.
- Prepare auditable channel-margin waterfalls covering manufacturer realization, carrying-and-forwarding agents, stockists, retailers, hospitals, rebates, trade schemes, taxes and logistics costs.
- Review contracts and promotional schemes for practices that could appear to inflate MRP while funding channel incentives.
- Model earnings sensitivity under lower MRP ceilings, capped retailer margins, reduced hospital mark-ups and mandatory pass-through of price reductions.
- Accelerate lower-MRP packs, transparent patient-assistance programs, generic alternatives and direct-to-patient channels where commercially viable.
- Strengthen pharmacy and hospital communications to distinguish medicine price, dispensing/service charges, storage costs and clinical administration charges.